ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer
Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer
New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforces earlier results in platinum-resistant ovarian cancer.
ESMO26: Halda buy delivers a win for J&J in prostate cancer
A drug at the heart of Johnson & Johnson's $3bn takeover of Halda has been shown to be "highly active" in a first-in-human prostate cancer trial.
ESMO26: BMS dual-acting ADC beats chemo in breast cancer
BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.
ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer
Two drugs hoping to muscle in on Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new trial readouts at ESMO.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Women in AI - an evening of practical AI learning
Women in AI returns November 10 in London, UK. Join women from across healthcare for an evening of practical AI learning.
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne
Europe's Largest Gathering for ADC Innovation
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community
PharmaMarketing Summit 2027 to Convene America's Top Pharmac...
Elite industry leaders will gather to address AI-driven engagement, launch excellence, and the future of market access at an exclusive, invitation-only event
3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...
The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights